Financials data is unavailable for this security.
View more
Year on year Enzon Pharmaceuticals Inc had revenues fall -100.00% from 26.00k to 0.00, though the company grew net income from a loss of 186.00k to a gain of 1.37m.
| Gross margin | -- |
|---|---|
| Net profit margin | 6,111.54% |
| Operating margin | -4,200.00% |
| Return on assets | 3.39% |
|---|---|
| Return on equity | 10.90% |
| Return on investment | 3.42% |
More ▼
Cash flow in USDView more
In 2023, Enzon Pharmaceuticals Inc did not generate a significant amount of cash. However, the company earned 1.31m from its operations for a Cash Flow Margin of --. In addition the company used on investing activities and also paid 1.28m in financing cash flows.
| Cash flow per share | -0.0091 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.6277 |
|---|---|
| Tangible book value per share | 0.6277 |
More ▼
Balance sheet in USDView more
| Current ratio | 113.75 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
SmartText is unavailable
| Div yield(5 year avg) | 11.65% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | -60.21 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 154.37 |
More ▼
